WO1999033980A3 - Membres de familles de tnf et de tnfr - Google Patents

Membres de familles de tnf et de tnfr Download PDF

Info

Publication number
WO1999033980A3
WO1999033980A3 PCT/US1998/027474 US9827474W WO9933980A3 WO 1999033980 A3 WO1999033980 A3 WO 1999033980A3 US 9827474 W US9827474 W US 9827474W WO 9933980 A3 WO9933980 A3 WO 9933980A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
members
proteins
tnfr
tnfr families
Prior art date
Application number
PCT/US1998/027474
Other languages
English (en)
Other versions
WO1999033980A2 (fr
WO1999033980A9 (fr
Inventor
Catherine Tribouley
David Pot
Altaf Kassam
George Lamson
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU20934/99A priority Critical patent/AU2093499A/en
Publication of WO1999033980A2 publication Critical patent/WO1999033980A2/fr
Publication of WO1999033980A9 publication Critical patent/WO1999033980A9/fr
Publication of WO1999033980A3 publication Critical patent/WO1999033980A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des membres de la superfamille TNF et TNFR de protéines qui ont été identifiés. Ces protéines vont servir de cibles pour une intervention ou mimétique thérapeutique. Les protéines TNF-L et TNFR-L peuvent servir à induire la mort des cellules et/ou la prolifération de cellules. Les membres de ces superfamilles sont associés à un large éventail de processus morbides, raison pour laquelle ils sont pris comme régulateurs biologiques et physiologiques centraux.
PCT/US1998/027474 1997-12-30 1998-12-22 Membres de familles de tnf et de tnfr WO1999033980A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20934/99A AU2093499A (en) 1997-12-30 1998-12-22 Members of tnf and tnfr families

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6895997P 1997-12-30 1997-12-30
US60/068,959 1997-12-30
US21227098A 1998-12-16 1998-12-16
US09/212,270 1998-12-16

Publications (3)

Publication Number Publication Date
WO1999033980A2 WO1999033980A2 (fr) 1999-07-08
WO1999033980A9 WO1999033980A9 (fr) 1999-10-14
WO1999033980A3 true WO1999033980A3 (fr) 1999-11-18

Family

ID=26749548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027474 WO1999033980A2 (fr) 1997-12-30 1998-12-22 Membres de familles de tnf et de tnfr

Country Status (2)

Country Link
AU (1) AU2093499A (fr)
WO (1) WO1999033980A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
EP1007659B1 (fr) 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Recepteurs 6 alpha & 6 beta du facteur de necrose tumorale
DE69837606T2 (de) 1997-09-12 2008-02-14 Biogen Idec Ma Inc., Cambridge Cystein-reiche rezeptoren-train
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
CN100340292C (zh) 1999-01-25 2007-10-03 比奥根艾迪克Ma公司 Baff,其封闭剂以及它们在b细胞应答的调节中的应用
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
AU777536B2 (en) * 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP2314694A3 (fr) 1999-08-17 2013-12-11 Biogen Idec MA Inc. Récepteur BAFF (BCMA), agent immunorégulateur
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
CA2408617A1 (fr) 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
AU2001279055A1 (en) 2000-07-27 2002-02-13 Genentech, Inc. Apo-2L receptor agonist and CPT-11 synergism
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
EP1401870A4 (fr) 2001-05-24 2006-04-19 Human Genome Sciences Anticorps contre le facteur de necrose tumorale delta (april)
AU2002366430B2 (en) 2001-07-03 2008-09-18 Genentech, Inc. Human DR4 antibodies and uses thereof
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
WO2004094620A2 (fr) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Recepteurs baff tronques
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
CA2554526A1 (fr) 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629244C (fr) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
WO2008034776A1 (fr) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Procédé de traitement du cancer présentant des mutations egfr
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CA2827859A1 (fr) 2011-02-28 2012-09-07 Genentech, Inc. Marqueurs biologiques et procedes de prediction de reponse a des antagonistes de lymphocytes b

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (fr) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Facteurs de necrose tumorale delta et epsilon chez l'homme
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5
WO1998055621A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (fr) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Facteurs de necrose tumorale delta et epsilon chez l'homme
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5
WO1998055621A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGGARWAL B.B. AND NATARAJAN K.: "Tumor necrosis factor: developments during the last decade", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01) - June 1996 (1996-06-01), pages 93 - 124, XP002094503 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002101204, Database accession no. AA682496 *
GRUSS H.-J. AND DOWER S.K.: "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas", BLOOD, vol. 85, no. 12, 15 June 1995 (1995-06-15), pages 3378 - 3404, XP002094502 *
GRUSS H.-J.: "Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, vol. 26, no. 3, 1996, pages 143 - 159, XP002094504 *

Also Published As

Publication number Publication date
AU2093499A (en) 1999-07-19
WO1999033980A2 (fr) 1999-07-08
WO1999033980A9 (fr) 1999-10-14

Similar Documents

Publication Publication Date Title
WO1999033980A3 (fr) Membres de familles de tnf et de tnfr
WO2000060079A3 (fr) Nouveaux membres des familles tnf et tnfr
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
CA2005016A1 (fr) Fragment d'adn contenant un promoteur de site de l'elongation de la chaine de polypeptide humaine de facteur-1.alpha. et plamisde d'expression contenant ce fragment d'adn
CA2145093A1 (fr) Inhibiteur therapeutique des cellules musculaires lisses
GR3015015T3 (en) Leukocyte poor red blood cell storage system.
NZ297537A (en) method for changing the cell characteristics of the female reproductive tract
Bloomfield et al. Enhanced release of inflammatory mediators from lithium‐stimulated neutrophils in psoriasis
DE68909958D1 (de) Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
Howell mtDNA recombination: what do in vitro data mean?
DE69022778D1 (de) Zellkultursubstrat, Bioreaktor mit Zellkultursubstrat und therapeutische Vorrichtung vom extrakorporalen Umlauftyp.
AU1820388A (en) Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
AU3584993A (en) Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
WO2000006735A8 (fr) HYBRIDES D'INTERFERON-$g(a)
Copeland et al. Regional localization of three convertases, PC1 (Nec-1), PC2 (Nec-2), and furin (Fur), on mouse chromosomes
WO2002014369A3 (fr) Polypeptides du domaine d5 humain de production de kinine s
Moore et al. Malic dehydrogenases in sea urchin eggs
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine
ATE118819T1 (de) Dna moleküle, welche plazentales rinder-lactogen- peptid und das pre-peptid kodieren und genetisch transformierte zellen, die diese moleküle enthalten.
Guglielmi et al. Prevalence of monoclonal Ig with λ light chains in chronic myelocytic leukaemia
DE69017870D1 (de) Pharmazeutische Zubereitungen, die 3-Oxygermylpropionsäurepolymere enthalten zur Hemmung von Zelldegeneration.
WO2001051509A3 (fr) Proteine 140 associee a shc (sap-140)
WO2001090160A3 (fr) Regulation de la serine/threonine kinase humaine analogue a p78
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase